Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

Enorama Pharma

0.45 SEK

-8.16 %

Less than 1K followers

ERMA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-8.16 %
-47.06 %
-76.44 %
-80.43 %
-82.56 %
-81.17 %
-91.88 %
-98.25 %
-92.93 %

Enorama Pharma is a pharmaceutical company. The company's operations are focused on producing and developing medical nicotine chewing gum. The products are sold mainly through retailers who sell the product under their own brand. The largest market is found in the Nordic region, but with a share of sales exported globally. Enorama Pharma was founded in 2006 and the headquarters are located in Malmö.

Read more
Market cap
33.56M SEK
Turnover
3.07K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
7/4
2026

Extraordinary general meeting '26

20/5
2026

Interim report Q1'26

19/8
2026

Interim report Q2'26

All
Press releases
ShowingAll content types
Regulatory press release3/20/2026, 1:45 PM

Enorama Pharma: BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING OF ENORAMA PHARMA AB (PUBL)

Enorama Pharma
Regulatory press release3/20/2026, 1:45 PM

Enorama Pharma: KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I ENORAMA PHARMA AB (PUBL)

Enorama Pharma
Regulatory press release3/18/2026, 7:30 AM

Bokslutskommuniké - Enorama Pharma AB (publ)

Enorama Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/17/2026, 2:00 PM

Kallelse till extra bolagsstämma tillika första kontrollstämma i Enorama Pharma AB (publ)

Enorama Pharma
Regulatory press release3/17/2026, 2:00 PM

Notice of extraordinary general meeting and first control meeting in Enorama Pharma AB (publ)

Enorama Pharma
Regulatory press release3/11/2026, 2:15 PM

The balance sheet for liquidation purposes shows that the equity in Enorama Pharma AB (publ) is less than half of the registered share capital and the board will convene a first control meeting

Enorama Pharma
Regulatory press release3/11/2026, 2:15 PM

Kontrollbalansräkning utvisar att det egna kapitalet i Enorama Pharma AB (publ) understiger hälften av det registrerade aktiekapitalet och styrelsen kommer att kalla till en första kontrollstämma

Enorama Pharma
Regulatory press release3/10/2026, 10:10 AM

Enorama Pharma AB (publ) senarelägger publicering av bokslutskommunikén för 2025

Enorama Pharma
Regulatory press release3/3/2026, 9:45 AM

Enorama Pharma AB (publ) withdraws notice and issues new notice of extraordinary general meeting

Enorama Pharma
Regulatory press release3/3/2026, 9:45 AM

Enorama Pharma AB (publ) drar tillbaka kallelse och utfärdar ny kallelse till extra bolagsstämma

Enorama Pharma
Regulatory press release3/3/2026, 9:30 AM

Enorama Pharma AB (publ) resolves to postpone the planned extraordinary general meeting

Enorama Pharma
Regulatory press release3/3/2026, 9:30 AM

Enorama Pharma AB (publ) beslutar att flytta den inplanerade extrastämman

Enorama Pharma
Regulatory press release2/19/2026, 2:00 PM

Kallelse till extra bolagsstämma i Enorama Pharma AB (publ)

Enorama Pharma
Regulatory press release2/19/2026, 2:00 PM

Notice of extraordinary general meeting in Enorama Pharma AB (publ)

Enorama Pharma
Regulatory press release2/18/2026, 11:00 AM

Enorama Pharma ingår låneavtal med huvudägaren DS Global om upp till 4 MUSD och förlänger befintligt låneavtal med samma ägare, under förutsättning av bolagsstämmas efterföljande godkännande

Enorama Pharma
Regulatory press release2/13/2026, 3:30 PM

Enorama Pharma AB (publ):s dotterbolag Enorama Pharma Inc. inleder rättsligt förfarande mot FDA avseende Refuse-to-File-beslut för NIC-S® PMTA

Enorama Pharma
Regulatory press release2/13/2026, 10:50 AM

Enorama Pharma AB (publ) postpones publication of its 2025 year-end report

Enorama Pharma
Regulatory press release2/13/2026, 10:50 AM

Enorama Pharma AB (publ) senarelägger publicering av bokslutskommunikén för 2025

Enorama Pharma
Regulatory press release2/13/2026, 10:45 AM

Enorama Pharma AB (publ) decides to prepare a balance sheet for liquidation purposes

Enorama Pharma
Regulatory press release2/13/2026, 10:45 AM

Enorama Pharma AB (publ) beslutar att upprätta kontrollbalansräkning

Enorama Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.